Xencor (XNCR) shares soared 7.3% in the last trading session to close at $9.25. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 13.6% gain over the past four weeks.The sudden price rise can be attributed to growing investor optimism related to the company’s efforts in developing engineered antibodies for the treatment of patients with cancer, as well as autoimmune and inflammatory diseases.This biotech developing antibodies for s ...

Company Performance - 4D Molecular Therapeutics reported a quarterly loss of $0.98 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.88, and compared to a loss of $0.63 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 98.58%, while revenues were zero a year ago [2] - The stock has added about 1.1% since the beginning of the year, underperforming the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.93 on revenues of $1.06 million, and for the current fiscal year, it is -$3.45 on revenues of $4.17 million [7] - The estimate revisions trend for 4D Molecular Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which 4D Molecular Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - Inotiv, Inc. reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of +20.00% [1] - The company posted revenues of $130.68 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.94% and showing an increase from year-ago revenues of $105.79 million [2] - Over the last four quarters, Inotiv has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Inotiv shares have declined approximately 49.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.08 on revenues of $130.9 million, and for the current fiscal year, it is -$0.86 on revenues of $499.62 million [7] Industry Outlook - The Medical - Drugs industry, to which Inotiv belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Inotiv's stock performance [5]

Company Performance - Indivior PLC reported quarterly earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and up from $0.44 per share a year ago, representing an earnings surprise of +96.15% [1] - The company posted revenues of $302 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 22.05%, compared to revenues of $299 million in the same quarter last year [2] - Over the last four quarters, Indivior has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Indivior shares have increased approximately 40% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.2% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $253.66 million, and for the current fiscal year, it is $1.21 on revenues of $1.02 billion [7] Industry Outlook - The Medical - Drugs industry, to which Indivior belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Insights - Zoetis is positioned to continue its earnings-beat streak, particularly in the upcoming earnings report, with a history of positive surprises in recent quarters [1][5] - The company reported earnings of $1.48 per share for the last quarter, exceeding the Zacks Consensus Estimate of $1.4 per share by 5.71% [2] - The previous quarter also saw a positive surprise, with actual earnings of $1.4 per share against an expected $1.37 per share, resulting in a 2.19% surprise [2] Earnings Estimates and Predictions - Estimates for Zoetis have been trending higher, supported by its history of earnings surprises [5] - The stock has a positive Zacks Earnings ESP of +1.10%, indicating bullish sentiment among analysts regarding the company's earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong likelihood of another earnings beat in the upcoming report [8] Earnings ESP and Market Behavior - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9]

Core Viewpoint - Ionis Pharmaceuticals (IONS) experienced a significant stock price increase of 9.1% to $43.59, driven by investor optimism regarding its drug portfolio and pipeline expansion [1][2]. Company Performance - The company is expected to report quarterly earnings of $0.19 per share, reflecting a year-over-year increase of 142.2%. Revenue is anticipated to be $246.31 million, up 9.5% from the same quarter last year [3]. - However, the consensus EPS estimate has been revised 5.5% lower over the past 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4]. Industry Context - Ionis Pharmaceuticals is part of the Zacks Medical - Drugs industry, where another company, Crinetics Pharmaceuticals, Inc. (CRNX), saw a 3.6% increase in its stock price but has returned -11.4% over the past month [5]. - Crinetics Pharmaceuticals has an unchanged consensus EPS estimate of -$1.13, representing a year-over-year change of -20.2% [6].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Catalyst Pharmaceutical (CPRX) - Catalyst Pharmaceutical currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [3] Price Performance - CPRX shares have increased by 1.92% over the past week, while the Zacks Medical - Drugs industry remained flat [5] - Over the past month, CPRX's price change is 8.02%, outperforming the industry's 3.76% [5] - In the last quarter, shares of CPRX have risen by 18.84%, and over the past year, they have gained 55.3%, compared to the S&P 500's increases of 2.37% and 14.4%, respectively [6] Trading Volume - The average 20-day trading volume for CPRX is 1,094,588 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, four earnings estimates for CPRX have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from $2.15 to $2.25 [9] - For the next fiscal year, three estimates have moved up, while one has been revised down [9] Conclusion - Considering the strong momentum indicators and positive earnings outlook, CPRX is identified as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [11]